Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$4.78
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.78
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.71 - $7.75
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$106.50M
Enterprise Value$38.49
Total Cash (Recent Filing)$50.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 18, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.25Price Target Upside219.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$2.71M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFast Track designation and IND acceptance for COYA 302 materially improve the program's development pathway, potentially speeding reviews, facilitating more regulator engagement and broader trial enrollment. These rulings reduce regulatory timeline risk and strengthen partnering appeal over months.
Low LeverageZero reported debt lowers financial risk and interest burden, giving the company flexibility to fund operations through equity or collaborations. For a clinical-stage biotech, conservative leverage preserves optionality and reduces the chance of distress if trials extend beyond current timelines.
Equity Funding AccessA $30M ATM program provides a flexible, on-demand way to raise capital without negotiated financings. Combined with recent private placement, this structural funding channel improves the company's ability to bridge clinical milestones and fund trials without immediate cash-flow generation.
Bears Say
Cash BurnPersistent negative operating and free cash flow mean the company will need external capital until operations become cash-generative. That structural cash burn increases dilution risk and places continual pressure on financing plans as trials and development consume resources.
Poor Profitability MetricsDespite recent revenue acceleration, gross profit remains low and net losses are large and sustained. Negative margins and returns on equity reflect an inability to convert revenue into earnings, limiting internal funding capacity and prolonging reliance on external financing.
Pipeline Concentration RiskBusiness outcomes are tightly tied to COYA 302 clinical progress; trial setbacks or slower enrollment would materially delay value creation. For a company lacking approved products, reliance on a single lead candidate raises binary outcome risk and amplifies funding and partnership dependency.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $106.50M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 28 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.096.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,184 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went up 2.632%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (219.04% Upside)
$15.25 (219.04% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.71%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$15.25
▲(219.04% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
4.45% Mutual Funds
24.25% Other Institutional Investors
62.70% Public Companies and
Individual Investors